{"id":"NCT00569582","sponsor":"Corcept Therapeutics","briefTitle":"A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome","officialTitle":"An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2011-01","completion":null,"firstPosted":"2007-12-07","resultsPosted":"2012-05-28","lastUpdate":"2013-08-22"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cushing's Syndrome"],"interventions":[{"type":"DRUG","name":"mifepristone","otherNames":["CORLUX"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.","primaryOutcome":{"measure":"Improvement in Diabetes and/or Glucose Intolerance.","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Mifepristone","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":["8734015","17984235","12381547","11502780","8888066","7693447","2991327","22466348","26507877","25013998","23970725"],"seeAlso":["http://www.corcept.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":50},"commonTop":["Nausea","Fatigue","Headache","Blood potassium decreased","Arthralgia"]}}